• Health & Medicine

Guest post: Are older cancer patients missing out on surgery?

John Butler is a Consultant Gynaecologist at the Royal Marsden Hospital. Here, he gives us his thoughts on new data on surgery in the NHS. John Butler is a Consultant Gynaecologist at the Royal Marsden Hospital. Here, he gives us his thoughts on new data on surgery in the NHS.

5 December 2014

• Health & Medicine

More progress in detecting oesophageal cancer early

We take a look at the latest data from a clinical trial testing a 'sponge on a string' as a new way to detect oesophageal cancer early. We take a look at the latest data from a clinical trial testing a 'sponge on a string' as a new way to detect oesophageal cancer early.

2 December 2014

• Science & Technology

Getting cancer’s story straight

In this guest post from one of our researchers we dig a bit deeper into cancer's genetic story and tackle the mystery of some missing pages. In this guest post from one of our researchers we dig a bit deeper into cancer's genetic story and tackle the mystery of some missing pages.

16 November 2014

• Science & Technology
• Health & Medicine

Crowdfunding cancer research – our latest experiment and how you can help

We've launched three exciting crowdfunding projects with our researchers. Will they receive the money they need? Only you can decide. We've launched three exciting crowdfunding projects with our researchers. Will they receive the money they need? Only you can decide.

14 November 2014

• Health & Medicine

It’s lung cancer awareness month

November is lung cancer awareness month, so we've pulled together key information about the disease and what we’re doing to improve survival. November is lung cancer awareness month, so we've pulled together key information about the disease and what we’re doing to improve survival.

9 November 2014

• Science & Technology
• Health & Medicine

Coming ever closer – first PARP inhibitor licensed in Europe

Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK? Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK?

24 October 2014

• Health & Medicine

Biotherapeutics - a new funding scheme for research

Our latest funding scheme focuses on the emerging field of biotherapeutics – smarter cancer treatments based on cells and biological molecules. Our latest funding scheme focuses on the emerging field of biotherapeutics – smarter cancer treatments based on cells and biological molecules.

21 October 2014

• Science & Technology

A chemical ‘breadcrumb trail’ helps melanoma spread

Our scientists have found that melanoma cells follow the ‘trail’ of a naturally-occurring molecule in the body, encouraging them to spread. Our scientists have found that melanoma cells follow the ‘trail’ of a naturally-occurring molecule in the body, encouraging them to spread.

14 October 2014

• Science & Technology
• Health & Medicine

Lung cancer evolution – a journey through space and time

Two new studies reveal the processes in our cells that cause lung cancers develop - a process that can take more than twenty years. Two new studies reveal the processes in our cells that cause lung cancers develop - a process that can take more than twenty years.

9 October 2014

• Science & Technology
• Health & Medicine

Citizen Science: “you don’t need to be qualified to do this”

To mark the launch of our latest Citizen Science game, Reverse The Odds, we caught up with one the researchers that you'll be helping by playing the game. To mark the launch of our latest Citizen Science game, Reverse The Odds, we caught up with one the researchers that you'll be helping by playing the game.

3 October 2014